GSK Sees Emerging Market Opportunity In Thinking Locally, Developing Locally
This article was originally published in The Pink Sheet Daily
U.K. drug maker is increasing its sales forces in emerging markets “very significantly”, even at a time when the company is reducing its sales force in U.S. and Europe.
You may also be interested in...
For about $670 million, GSK acquires UCB drugs and infrastructure in several dozen non-BRIC markets.
With growth slowing to a crawl in their largest markets, most major drug firms are focusing significant resources in emerging markets - now providing roughly one-third of the industry's growth, double its share two years ago
HONG KONG - GlaxoSmithKline announced Nov. 21 a joint venture with Shenzhen Neptunus Interlong Bio-Technique to develop flu vaccines aimed at strains specific to China, Hong Kong and Macau